Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Telix Pharmaceuticals Limited - American Depositary Shares
(NQ:
TLX
)
9.710
-0.170 (-1.72%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Telix Pharmaceuticals Limited - American Depositary Shares
< Previous
1
2
3
4
Next >
Telix to Host Investor Day in New York City on June 11, 2025
May 22, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
May 07, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
April 28, 2025
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Reports US$186M Q1 Revenue, Up 62% YOY
April 22, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
April 16, 2025
Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.
Via
Benzinga
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
April 15, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
April 13, 2025
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.
Via
Benzinga
Telix Announces Cardinal Health for Gozellix Commercial Distribution
April 08, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Five Below, Telix Pharmaceuticals, Dollar Tree And Other Big Stocks Moving Higher On Monday
April 07, 2025
Via
Benzinga
Telix Appoints Paul Schaffer as Chief Technology Officer
April 07, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Anne Whitaker Appointed as Non-Executive Director
April 03, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
April 01, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®
April 01, 2025
From
Telix ARTMS, Inc.
Via
GlobeNewswire
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
March 21, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
March 17, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Adds Lead-212 Isotope Production Capability
March 12, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
March 03, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
February 25, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
February 25, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Bridge Investment Group, Telix Pharmaceuticals, Sun Communities, And Other Big Stocks Moving Higher On Monday
February 24, 2025
Via
Benzinga
Stock Rebound Stalls; Nasdaq Down Triple Digits
February 24, 2025
Stocks have pulled back from their premarket gains, with the Nasdaq Composite down 163 points and oscillating in and out of negative territory for 2025.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
February 20, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)
February 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Illuccix® Approved in the United Kingdom
February 12, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 10, 2025
Via
Benzinga
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
January 30, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Completes Acquisition of RLS (USA) Inc.
January 27, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
SLB Posts Upbeat Results, Joins Bank OZK, Qorvo And Other Big Stocks Moving Higher On Friday
January 17, 2025
Via
Benzinga
Illuccix® Receives European Approval
January 16, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.